Frontiers in Cellular and Infection Microbiology,
Год журнала:
2024,
Номер
14
Опубликована: Апрель 10, 2024
Diabetes
mellitus
(DM)
refers
to
a
group
of
chronic
diseases
with
global
prevalence,
characterized
by
persistent
hyperglycemia
resulting
from
various
etiologies.
DM
can
harm
organ
systems
and
lead
acute
or
complications,
which
severely
endanger
human
well-being.
Traditional
treatment
mainly
involves
controlling
blood
sugar
levels
through
replacement
therapy
drugs
insulin;
however,
some
patients
still
find
satisfactory
curative
effect
difficult
achieve.
Extensive
research
has
demonstrated
close
correlation
between
enteric
dysbacteriosis
the
pathogenesis
types
DM,
paving
way
for
novel
therapeutic
approaches
targeting
gut
microbiota
manage
DM.
Fecal
transplantation
(FMT),
method
re-establishing
intestinal
microbiome
balance,
offers
new
possibilities
treating
diabetes.
This
article
provides
comprehensive
review
microbiota,
as
well
current
advancements
in
FMT
using
an
illustrative
example.
study
aims
offer
perspectives
establish
theoretical
foundation
clinical
diagnosis
management
Biology,
Год журнала:
2025,
Номер
14(3), С. 267 - 267
Опубликована: Март 6, 2025
Epithelial
linings
are
crucial
for
the
maintenance
of
physiological
barriers.
The
intestinal
epithelial
barrier
(IEB)
consists
enterocytes
through
tight
junctions
and
mucus-secreting
cells
can
undergo
modifications
throughout
life.
To
reproduce
as
closely
possible
IEB
main
features
over
time,
in
vitro
co-cultures
Caco2/HT-29
70/30
formed
by
parental
Caco2
HT-29
sub-cultivated
more
than
40
passages
were
set
up.
measurements
transepithelial
electrical
resistance
(TEER)
identified
two
populations:
TEER
(PC)
with
values
>
50
Ωcm2
fewer
passages,
leaky
(LC)
<
passages.
In
LC,
paracellular
permeability
increased
parallel.
By
immunofluorescence
Western
blot
analysis,
an
increase
claudin
2
was
observed
LC
vs.
PC,
no
differences
occludin
expression.
MUC-2
immunoreactivity
stronger
PC
LC.
also
showed
enhanced
vulnerability
to
TNFα+IFN-γ.
These
results
morpho-functional
reported
human
leaky/aged
gut
support
usefulness
our
cell
model
studying
molecular
processes
underlying
these
testing
drug/nutraceutical
treatments
ameliorate
aging.
Circulation Research,
Год журнала:
2023,
Номер
132(12), С. 1674 - 1691
Опубликована: Июнь 8, 2023
Cardiometabolic
disease
comprises
cardiovascular
and
metabolic
dysfunction
underlies
the
leading
causes
of
morbidity
mortality,
both
within
United
States
worldwide.
Commensal
microbiota
are
implicated
in
development
cardiometabolic
disease.
Evidence
suggests
that
microbiome
is
relatively
variable
during
infancy
early
childhood,
becoming
more
fixed
later
childhood
adulthood.
Effects
microbiota,
development,
life,
may
induce
changes
host
metabolism
modulate
risk
mechanisms
predispose
toward
In
this
review,
we
summarize
factors
influence
gut
composition
function
life
explore
how
microbial
throughout
life.
We
highlight
limitations
current
methodology
approaches
outline
state-of-the-art
advances,
which
improving
research
building
refined
diagnosis
treatment
options
microbiome-targeted
therapies.
Applied Microbiology,
Год журнала:
2023,
Номер
4(1), С. 47 - 69
Опубликована: Дек. 26, 2023
The
gastrointestinal
tract
is
an
environment
that
hosts
various
microorganisms,
including
pathogens.
Generally,
pathogenic
bacteria
enter
the
host
body
through
food
and
tract.
These
can
colonize
or
infiltrate
cells
tissues,
causing
infectious
diseases.
In
recent
years,
protective
role
of
probiotic
against
pathogens
has
been
carefully
investigated.
Probiotics
have
found
to
modulate
intestinal
microbial
flora
play
a
significant
in
tract’s
function,
especially
by
inhibiting
growth
bacteria.
However,
mechanism
action
probiotics
yet
be
sufficiently
proven
recognized.
Several
important
mechanisms
support
antagonistic
effects
on
which
achieved,
for
example,
production
different
antimicrobial
compounds,
such
as
bacteriocins,
organic
acids,
antibiotics,
proteins,
exopolysaccharides;
mucosal
barriers
with
mucosa
binding
blockers;
competition
nutrient
uptake;
strengthening
immune
system.
Accordingly,
this
review
summarizes
studies
examined
their
beneficial
preventing
bacterial
improving
functions.
Comprehending
allows
selection
appropriate
strains
specific
applications
dysfunction.
Abstract
There
is
a
large
pool
of
ideas
in
both
mainstream
and
non‐mainstream
medicine
on
how
diet
can
be
manipulated
order
to
treat
or
prevent
illnesses.
Despite
this,
our
understanding
specific
changes
influence
the
structure
function
gastrointestinal
tract
limited.
This
review
aims
describe
two
areas
that
might
provide
key
information
integrity
tract.
First,
demystifying
“leaky
gut
syndrome”
requires
rational
application
interpretation
tests
intestinal
barrier
function.
Multiple
ways
measuring
have
been
described,
but
inherent
difficulties
translation
from
animal
studies
humans
created
misinterpretations
misconceptions.
The
intrinsic
nature
dynamic.
seldom
considered
assessment.
To
adequately
understand
effects
dietary
interventions
function,
background
different
regions
dynamic
responses
stressors
(such
as
psychological
stress)
should
assessed
minimum.
Second,
ultrasound,
which
now
established
assessment
monitoring
inflammatory
bowel
disease,
has
hitherto
poorly
evaluated
assessing
real‐time
novel
aspects
patients
with
disorders
gut‐brain
interaction.
In
conclusion,
more
complete
functional
structural
profile
these
investigations
enable
permit
greater
manipulation
clinically
relevant
that,
amongst
other
advantages,
opportunities
for
personalized
health
care
delivery.
Seminars in Cancer Biology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Pancreatic
cancers
have
high
mortality
and
rising
incidence
rates
which
may
be
related
to
unhealthy
western-type
dietary
lifestyle
patterns
as
well
increasing
body
weights
obesity
rates.
Recent
data
also
suggest
a
role
for
the
gut
microbiome
in
development
of
pancreatic
cancer.
Here,
we
review
experimental
observational
evidence
roles
oral,
intratumoural
microbiomes,
impaired
barrier
function
exposure
inflammatory
compounds
metabolic
dysfunction
contributors
disease
with
focus
on
ductal
adenocarcinoma
initiation
progression.
We
highlight
some
emerging
editing
techniques
currently
being
investigated
context
disease.
Notably,
while
is
significantly
altered
PDAC
its
precursor
diseases,
utility
diagnostic
prognostic
tool
hindered
by
lack
reproducibility
potential
reverse
causality
case-control
cohorts.
Future
research
should
emphasise
longitudinal
mechanistic
studies
integrating
multi-omics
unravel
complex
host-microbiome
interactions.
This
will
allow
deeper
aetiologic
insights
that
can
inform
treatments
guide
public
health
recommendations.
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(7), С. 2483 - 2483
Опубликована: Апрель 5, 2025
Background:
Patients
with
irritable
bowel
syndrome
(IBS)
often
experience
comorbid
psychological
conditions,
notably
depression
and
anxiety.
Evidence
suggests
that
these
conditions
are
linked
to
gut
barrier
dysfunction,
dysbiosis,
chronic
inflammation.
All
factors
central
IBS
pathophysiology
mood
disturbances.
Polyunsaturated
fatty
acids
(PUFAs)
play
crucial
roles
in
modulating
inflammation
depression.
This
study
examined
the
associations
among
intestinal
permeability,
PUFA
profiles,
low-grade
inflammation,
severity
patients
diarrhea
(IBS-D).
Methods:
Forty-three
IBS-D
(7
men,
36
women;
44.56
±
1.52
years)
were
categorized
into
depressed
(IBS-D(d+))
non-depressed
(IBS-D(d-))
groups
according
scores
on
subscale
of
Symptom
Checklist-90-Revised
(SCL-90-R).
Biomarkers
small
permeability
(s-IP)
assessed
urine
blood,
alongside
erythrocyte
membrane
composition,
indices.
Results:
(d+)
exhibited
elevated
s-IP
altered
metabolism
compared
their
(d-)
counterparts.
Additionally,
first
group,
omega-3
concentrations
inversely
correlated
biomarkers,
while
omega-6/omega-3
ratio
showed
a
positive
correlation.
Moreover,
is
significantly
associated
markers
levels.
Lastly,
higher
levels
dysbiosis
pro-inflammatory
cytokines
than
patients.
Conclusions:
These
findings
highlight
interplay
between
integrity
depression,
suggesting
profiles
could
represent
novel
therapeutic
targets
for
managing
this
population.
was
registered
ClinicalTrials.gov
(NCT03423069),
date
registration
30
January
2018.